What GLP-1 Medicines Don't Do

The before-and-after photographs leave a lot out. They do not show the first six weeks of nausea, the meal abandoned half-eaten because the stomach simply refused it, or the worry about what happens when the prescription ends. They do not show the person who lost weight quickly and lost more muscle than they should have along the way. The pictures are real, but they are the edited highlights of something more complicated.

The previous article in this section explained how GLP-1 medicines work. This one is about their boundaries, because a treatment is only as trustworthy as the honesty surrounding it. None of what follows is an argument against these drugs. It is the other half of an honest account — the half that marketing, by its nature, tends to omit.

The side effects that are common

For most people who experience problems, the trouble is the gut. Nausea is the headline symptom, especially in the first weeks and after each dose increase. Vomiting, diarrhoea, constipation, bloating and reflux are all common. These effects flow directly from the mechanism — a stomach that empties more slowly — and they usually ease as the body adjusts and as the dose is escalated gradually, which is exactly why the dose is escalated gradually rather than started high.

For a minority, the side effects are severe enough that the medicine cannot be tolerated, and that is a legitimate outcome rather than a failure of effort. There is also a practical hazard worth naming: persistent vomiting or poor fluid intake can lead to dehydration, which in turn can strain the kidneys. This is not common, but it is the kind of thing that turns a manageable side effect into something that needs medical attention.

The less common but more serious signals

Beyond the everyday gut symptoms sit a few rarer concerns that any honest account has to include.

Gallbladder problems, including gallstones and gallbladder inflammation, occur more often in people on these medicines and in people losing weight rapidly generally — rapid weight loss is itself a risk factor for gallstones, independent of the drug. New, severe, persistent pain in the upper-right abdomen deserves prompt assessment.

Pancreatitis — inflammation of the pancreas — has been a watched-for signal with this class. The overall risk appears low, but the symptom to know is unmistakable when it matters: severe, persistent abdominal pain, often radiating to the back and frequently with vomiting. That combination is a reason to seek urgent medical care, not to wait and see.

There are also specific contraindications that mean these drugs are not suitable for some people at all — including a personal or family history of certain rare thyroid cancers (medullary thyroid carcinoma) and a particular endocrine syndrome, MEN 2. They are not used in pregnancy. This is precisely why a prescriber takes a full history before starting treatment, and why self-sourcing from an online vial — bypassing that assessment entirely — is so hazardous.

What happens when you stop

Here is the fact that the photographs most conspicuously omit: for many people, the weight comes back when the medicine stops.

The clearest data come from the extension of the first major semaglutide trial. When participants who had lost substantial weight on the drug stopped taking it, they regained, on average, around two-thirds of the lost weight within roughly a year, and much of the improvement in metabolic markers reversed alongside it. This is not a moral failure or a sign the drug "didn't really work". It is the predictable consequence of treating a chronic condition with a treatment and then withdrawing it. The appetite signal the drug was suppressing returns, because the underlying biology was never abolished — only managed.

This reframes the whole proposition. A GLP-1 is far closer to a blood-pressure medicine than to a course of antibiotics. Blood-pressure tablets do not cure hypertension; they control it for as long as they are taken. Whether, when and how treatment might ever be reduced or stopped is a clinical decision made with a prescriber over time, weighed against the individual's circumstances — not something to assume, and certainly not something this article can advise on for any particular person.

The muscle question

Rapid weight loss of any kind — diet, surgery or drugs — costs some lean tissue as well as fat. A portion of the weight lost on GLP-1 medicines is muscle, and that matters, particularly in older people, in whom muscle loss carries real consequences for strength, mobility and long-term independence.

This is not a reason to fear the drugs, but it is a reason the surrounding care matters. Adequate protein intake and resistance exercise during weight loss are the established ways to preserve lean mass, and they become more important, not less, when appetite is pharmacologically suppressed and total food intake falls. The next article in this section is devoted entirely to this, because it is the single most under-discussed aspect of treatment.

The things no drug can outsource

Finally, the quiet limits. A GLP-1 reduces appetite; it does not improve the quality of what is eaten, and it is entirely possible to eat less of a poor diet. It does nothing for sleep, for stress, for activity, or for the broader food environment that shaped the problem in the first place. It does not treat the relationship with food, where that is part of the picture. It reduces one powerful driver of overeating — and leaves the rest of health exactly where it was.

This is why these medicines work best as one component of a wider plan rather than a replacement for it, and why the trials that produced the headline results all paired the drug with structured lifestyle support. The medicine does something genuinely difficult that lifestyle advice alone often cannot. It does not do everything, and it was never meant to.

Practical takeaways

• Gut side effects — nausea, vomiting, diarrhoea, constipation — are common, usually ease with gradual dose increases, and occasionally prevent treatment altogether.
• Rarer but serious concerns include gallbladder disease and a pancreatitis signal; severe persistent abdominal pain needs urgent assessment.
• Specific contraindications exist, which is why a full clinical history before starting matters and self-sourcing is dangerous.
• Weight is commonly regained after stopping (STEP 1 extension) — these are long-term treatments for a chronic condition, not a finite course.
• Some of the weight lost is muscle; protein and resistance training during treatment matter more, not less.

What this doesn't mean

None of this means GLP-1 medicines are unsafe or not worth taking. For the right person, under supervision, the benefits can be substantial and well evidenced. It means the decision deserves the full picture, including the limits — and that the right person is identified by a clinician, not by a checkout page.

When to seek medical advice

Seek urgent medical care for severe, persistent abdominal pain (especially radiating to the back, or with vomiting), signs of significant dehydration, or symptoms of gallbladder trouble such as severe upper-right abdominal pain. More generally, any decision to start, change or stop one of these medicines belongs with a qualified prescriber who knows your full history — not with this article, and not with an online seller.

A closing thought

A drug that reliably reduces appetite is a genuine advance, and pretending otherwise helps nobody. But the honest version of the story includes the nausea, the regain, the muscle, and the boundaries — because a treatment described only by its best photographs is being sold rather than explained. People deserve the explanation.

Further reading and sources

• MHRA — Drug Safety Update entries and product information for GLP-1 receptor agonists
• BNF (British National Formulary) — cautions, contraindications and adverse effects for this drug class
• STEP 1 extension — data on weight regain after discontinuation of semaglutide
• NICE TA875 and TA1026 — technology appraisals on GLP-1 medicines for weight management
• Endocrine Society — clinical guidance on obesity management and treatment limitations

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.